Claims for Patent: 9,572,861

Summary for Patent: 9,572,861

Title:	Engineered polypeptide agents for targeted broad spectrum influenza neutralization
Abstract:	The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.
Inventor(s):	Sasisekharan; Ram (Lexington, MA), Viswanathan; Karthik (Waltham, MA), Soundararajan; Venkataramanan (Windham, NH), Raguram; S. (Hillsborough, NJ), Sasisekharan; Viswanathan (Cambridge, MA), Subramanian; Vidya (Somerville, MA)
Assignee:	Massachusetts Institute of Technology (Cambridge, MA)
Application Number:	15/094,522
Patent Claims:	1. A method of making a pharmaceutical composition comprising the step of: formulating an infold agent with one or more inactive agents or additives, wherein the infold agent comprises an infold selected from the group consisting of Infold-1, Infold-2, Infold-3, Infold-4, Infold-5, Infold-6, Infold-7, Infold-8, Infold-9, Infold-10, Infold-11, Infold-12, Infold-13, Infold-14, Infold-15, Infold-16, Infold-17, Infold-18, Infold-19, Infold-20, Infold-21, Infold-22, Infold-23, Infold-24, Infold-25, Infold-26, Infold-27, Infold-28, Infold-29, Infold-30, Infold-31, Infold-32, Infold-33, Infold-34, Infold-35, Infold-36, Infold-37, Infold-38, Infold-39, and Infold-40 to provide a pharmaceutical composition comprising at least one unit dose of the infold agent. 2. The method of claim 1, wherein the inactive agent is a sterile biocompatible carrier. 3. The method of claim 2, where the sterile biocompatible carrier is selected from one or more of sterile water, saline, buffered saline, and dextrose solution. 4. The method of claim 1, wherein the additive is selected from one or more of stabilizer, excipient, and preservatives. 5. The method of claim 4, wherein the excipient is selected from one or more of sugars and amino acids. 6. The method of claim 1, wherein the pharmaceutical composition is formulated for administration by a route selected from the group consisting of oral, intravenous, intramuscular, intra-arterial, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical, mucosal, nasal, buccal, enteral, sublingual, intratracheal or bronchial. 7. The method of claim 6, wherein the administration is by intratracheal or bronchial instillation. 8. The method of claim 6, wherein the administration is by inhalation. 9. The method of claim 1, wherein the pharmaceutical composition is formulated as an oral spray, a nasal spray, or an aerosol. 10. The method of claim 6, wherein the administration is by oral. 11. The method of claim 1, wherein the pharmaceutical composition comprises an oral spray, a nasal spray or an aerosol.

Details for Patent 9,572,861

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2030-01-27